[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100491797":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":24,"locations":33,"responsibleParty":47,"collaborators":50,"id":55,"slug":56,"hasResults":57,"nctId":58,"briefTitle":59,"officialTitle":59,"acronym":60,"eligibilityCriteria":61,"healthyVolunteers":57,"sex":62,"minAge":63,"maxAge":11,"enrollmentInfo":64,"targetDuration":11,"studyType":67,"phases":68,"briefSummary":70,"conditions":71,"keywords":75,"overallStatus":35,"whyStopped":11,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":82,"completionDateStruct":84,"leadSponsor":86,"locationsCount":87},{"fullName":5,"class":6},"University of Vermont Medical Center","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Single arm study","EXPERIMENTAL",null,[13],"Drug: Apixaban",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":11},"DRUG","Apixaban","Open label",[9],[21],{"name":22,"affiliation":5,"role":23},"Alissa A Thomas, MD","PRINCIPAL_INVESTIGATOR",[25,29],{"name":22,"role":26,"phone":27,"phoneExt":11,"email":28},"CONTACT","802-847-8400","alissa.thomas@med.uvm.edu",{"name":30,"role":26,"phone":31,"phoneExt":11,"email":32},"Donna Silver","802-656-5040","irb@uvm.edu",[34],{"facility":5,"status":35,"city":36,"state":37,"zip":38,"country":39,"countryCode":40,"cosmosGeoPoint":41,"geoPoint":46,"contacts":11},"RECRUITING","Burlington","Vermont","05401","United States","US",{"type":42,"coordinates":43},"Point",[44,45],-73.21207,44.47588,{"lat":45,"lon":44},{"type":23,"investigatorFullName":48,"investigatorTitle":49,"investigatorAffiliation":5,"oldNameTitle":11,"oldOrganization":11},"Alissa Thomas","Associate Professor of Neurological Sciences",[51,53],{"name":52,"class":6},"Dartmouth-Hitchcock Medical Center",{"name":54,"class":6},"MaineHealth","100491797","phase-2-venous-thromboembolism-prevention-in-outpatients-with-glioma-100491797",false,"NCT05683808","Venous Thromboembolism Prevention in Outpatients With Glioma","VTE-POG","Inclusion Criteria:\n\n* Histologic diagnosis of malignant glioma, World Health Organization (WHO) grade 4, including glioblastoma and astrocytoma, based on recent biopsy or resection.\n* Age 18 and old\n* Karnofsky performance status (KPS) 60-100\n* Acceptable labs, including platelets of greater than or equal to 100,000, glomerular filtration rate (GFR) greater than or equal to 25.\n* Ability to provide informed consent.\n* Planning for treatment with radiation and chemotherapy.\n\nExclusion Criteria:\n\n* Evidence of deep venous thrombosis (DVT), pulmonary embolism (PE), or cerebral vein thrombosis (CVT) within 6 months prior to enrollment on the study.\n* Pregnancy.\n* Significant bleeding risk including: history of symptomatic intracranial hemorrhage, active bleeding at time of study registration, clinically significant bleeding within 14 days of study registration, intracranial trauma in the past 6 months, including stroke or traumatic brain injury, major surgery or major procedure within 48 hours.\n* Allergy to apixaban or contraindication to prophylactic anticoagulation. Contraindications include patients who are currently on unfractionated heparin, low molecular weight heparin, heparin derivatives (examples: fondaparinux), or other direct oral anticoagulants (examples: dabigatran, edoxaban, rivaroxaban), who are either unable or unable to discontinue these agents in favor of the investigational drug. Apixaban is also contraindicated in patients who are on strong CYP3A4 inhibitor and P-glycoprotein inhibitors.\n* Indication for full anticoagulation (i.e. atrial fibrillation, mechanical valve, etc.).\n* Estimated life expectancy of \\\u003C3 months.","ALL","18 Years",{"count":65,"type":66},40,"ESTIMATED","INTERVENTIONAL",[69],"PHASE2","This is an open label study of apixaban for venous thromboembolism prevention in patients with newly diagnosed grade 4 glioma.",[72,73,74],"Glioblastoma","Astrocytoma","Venous Thromboembolism",[76,72,73,77,17],"High grade glioma","Venous thromboembolism","2026-01-27",{"date":80,"type":81},"2026-01-30","ACTUAL",{"date":83,"type":81},"2023-01-16",{"date":85,"type":66},"2027-06-30",{"name":5,"class":6},1]